Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,974 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07290088RecruitingPhase 2/Phase 3
Testing a new drug for advanced solid tumors
This trial tests a new drug called PRL3-zumab for people with advanced solid tumors (cancers that have spread). The goal is to see if it can shrink tumors or slow their growth. It is an option for patients who have had limited prior treatments.
Kota BharuAges 18–75 - NCT06453486RecruitingPhase 2
High dose radiation for pancreatic cancer after chemo
This trial tests whether giving a strong, focused dose of radiation can help people with locally advanced pancreatic cancer that has shrunk or stayed stable with first-line chemotherapy. It aims to improve outcomes for those who cannot have surgery.
Toronto, OntarioAges 18 years+ - NCT07269145RecruitingPhase 1
Testing TQB3122 capsules in advanced solid tumors
This trial tests an experimental oral capsule (TQB3122) for safety and early signs of effectiveness in people with advanced solid tumors that have not responded to standard therapies. It is for patients who are relatively healthy and have specific cancer types like ovarian, breast, or prostate cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07266428RecruitingPhase 1/Phase 2
Study of a new drug (OTP-01) for advanced solid tumors
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT07467928Recruiting
AI colonoscopy's long-term effect on advanced polyps
This study looks at how well AI-assisted colonoscopy prevents new advanced polyps from forming over the long term. It's for people who were in our earlier AI colonoscopy study and are healthy enough for a follow-up scope.
Hong KongAges 18 years+ - NCT07180264Recruiting
Trastuzumab deruxtecan for advanced breast cancer
This trial tests a targeted therapy called trastuzumab deruxtecan for people with advanced breast cancer. It aims to see how well the treatment works and how safe it is.
ShanghaiAges 18 years+ - NCT07180160RecruitingPhase 2
A study of QL1706 for HR-positive, HER2-negative breast cancer
This trial tests a new drug combination (iparomlimab and tuvonralimab, also called QL1706) for people with advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if standard treatments have stopped working.
ShanghaiAges 18 years+ - NCT06463340RecruitingPhase 1
Study of SGR-3515 for advanced solid tumors
This trial tests a new drug called SGR-3515 for people with advanced solid tumors. It aims to see if the drug is safe and how it works in the body.
New Haven, ConnecticutAges 18 years+ - NCT06258304RecruitingPhase 1
Testing a new immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug, GIGA-564, for people with advanced solid tumors that have not responded to or have returned after standard treatments. The goal is to see if the drug is safe and effective, and to find the best dose.
Bethesda, MarylandAges 18 years+ - NCT06856200Recruiting
Sirolimus plus palbociclib and fulvestrant for advanced breast cancer
This trial tests a new combination of three drugs (sirolimus, palbociclib, and fulvestrant) for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The goal is to see if adding sirolimus can help control the cancer when standard hormone therapy is no longer working.
ShanghaiAges 18 years+ - NCT06158477RecruitingPhase 1
A study of JYP0035 for advanced solid tumors
This trial tests a new drug called JYP0035 alone in people with advanced solid tumors. It aims to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–74 - NCT06468098RecruitingPhase 1
Study of IBI363 for advanced cancer
This trial tests a new drug called IBI363 for people with advanced cancer that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05970016RecruitingPhase 1/Phase 2
Study for advanced solid cancers with a DNA repair target
This Phase I/II trial tests an investigational treatment in people with advanced solid tumors that have grown despite standard therapy, or where standard options aren’t available. In later Phase II, the trial mainly enrolls patients whose tumor shows a specific DNA repair problem (DDR defect).
Beijing, Beijing MunicipalityAges 18–70 - NCT05698459RecruitingPhase 1
Study of a virus treatment delivered into liver arteries
This Phase 1 study tests an oncolytic (tumor-attacking) virus given directly into liver arteries using a catheter. It’s for people with advanced liver cancer who have already tried standard treatments or can’t have them, aiming to assess safety and early anti-cancer activity.
Wuhan, HubeiAges 18–75 - NCT07004296RecruitingPhase 1
Study of HDM2005 for advanced solid tumors
This trial tests a new drug, HDM2005, in people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective for tumors that show a specific marker called ROR1.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07480733RecruitingPhase 2
Study of two drugs for advanced solid tumors
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07016490RecruitingPhase 1
Study of SSGJ-709 for advanced solid tumors
This trial tests a new drug called SSGJ-709 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
AdelaideAges 18 years+ - NCT06398444RecruitingPhase 2/Phase 3
Lutetium-177 treatment for advanced neuroendocrine tumors
This trial tests a radioactive drug called Lutetium-177 Oxodotreotide (a type of PRRT) for people with advanced neuroendocrine tumors that have already been treated with other therapies and are still growing. The drug targets somatostatin receptors on tumor cells to deliver radiation directly to the cancer.
Shanghai, Shanghai MunicipalityAges 12 years+ - NCT06978114RecruitingPhase 2
Study of a new drug for advanced bile duct cancer
This trial tests a new drug called BL-B01D1 combined with an immunotherapy for people with advanced bile duct cancer. It aims to see if this combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06248411RecruitingPhase 1
Study of KK2260 for advanced solid tumors
This study tests a new experimental drug, KK2260, for people with advanced or advanced solid tumors, especially esophageal cancer and certain head and neck cancers. The goal is to see if the drug is safe and helps shrink or control the cancer.
Nagoya, Aichi-kenAges 18 years+ - NCT06768151RecruitingPhase 1
CEA-targeting car-t therapy for advanced lung cancer
This trial tests a new treatment called CAR-T therapy that targets a protein called CEA found on some lung cancer cells. It is for people with advanced lung cancer that has not responded to or has gotten worse after at least two standard treatments.
Wuhan, HubeiAges 18 years+ - NCT06474455RecruitingPhase 1/Phase 2
Study of SHR-9839 with other treatments for advanced solid tumors
This trial tests a new drug called SHR-9839 combined with other cancer treatments for people with advanced solid tumors, including a certain type of lung cancer. The goal is to see if the combination is safe and effective against the cancer.
Zhengzhou, HenanAges 18–75 - NCT06264180RecruitingPhase 3
Viral therapy and nivolumab for advanced melanoma
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
Gilbert, ArizonaAges 12 years+ - NCT06654440RecruitingPhase 2
Testing SHR-A2102 for advanced gynecological cancers
This trial tests a new targeted drug, SHR-A2102, for people with advanced gynecological cancers (like ovarian, uterine, or cervical) that have not responded to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells, which may help control the cancer.
Guangzhou, GuangdongAges 18–75
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,974 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.